SCHEMBL475981

SCHEMBL475981

C=CCn1c(N)c(C(=S)S)c(=O)n(CC=C)c1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.46
ADORA2B P29275 3/20 0.39
ADORA2A P29274 2/20 0.39
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
NPSR1 Q6W5P4 2/20 0.35
ALDH1A1 P00352 4/20 0.33
POLB P06746 1/20 0.33
LMNA P02545 1/20 0.33
GRK6 P43250 1/20 0.32
MAPT P10636 3/20 0.32
KDM4E B2RXH2 3/20 0.32
HIF1A Q16665 2/20 0.32
GLA P06280 2/20 0.32
GAA P10253 2/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4759502 0.74 CYP3A4 (0.58) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6
SCHEMBL6571379 0.69 CYP3A4 (0.50) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6
SCHEMBL28662 0.66 CYP3A4 (1.00) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6
SCHEMBL10616188 0.66 CYP3A4 (0.50) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6
SCHEMBL9278909 0.62 KDM4E (0.43) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6
SCHEMBL24669059 0.62 CYP3A4 (0.76) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6
SCHEMBL21592085 0.62 CYP3A4 (0.76) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6
SCHEMBL713076 0.62 CYP3A4 (0.76) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6
Acetone SCHEMBL11800599 0.62 CYP3A4 (0.76) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6
SCHEMBL2778902 0.61 CYP3A4 (0.44) CYP3A4ADORA2BADORA2ACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575178-B2 Isothiazolo-pyrimidinedione derivatives as TRPA1 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-11-05 US disclosed
EP-2411397-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2012-02-01 EP disclosed
US-20120010223-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2012-01-12 US disclosed
WO-2010109328-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPA1 MODULATORS GLENMARK PHARMACEUTICALS, S.A. (CH) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010223-A1 ISOTHIAZOLO-PYRIMIDINEDIONE DERIVATIVES AS TRPAI MODULATORS TRPA1, TRPV1, TRPC3 CYP3A4 1550/4885ADORA2B 133/4885ADORA2A 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.